Related references
Note: Only part of the references are listed.Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse et al.
DIABETOLOGIA (2020)
Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial
Daisuke Yabe et al.
Lancet Diabetes & Endocrinology (2020)
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial
Yuichiro Yamada et al.
Lancet Diabetes & Endocrinology (2020)
The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes
Mads Frederik Rasmussen
DIABETOLOGY INTERNATIONAL (2020)
Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea The PIONEER 3 Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects
Tine A. Baekdal et al.
CLINICAL PHARMACOKINETICS (2019)
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
Vanita R. Aroda et al.
DIABETES CARE (2019)
Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example
Vanita R. Aroda et al.
DIABETES OBESITY & METABOLISM (2019)
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Richard Pratley et al.
LANCET (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial
Thomas R. Pieber et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
Ofri Mosenzon et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
Bernard Zinman et al.
DIABETES CARE (2019)
Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes
Charlotte Granhall et al.
CLINICAL PHARMACOKINETICS (2019)
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials
V. R. Aroda et al.
DIABETES & METABOLISM (2019)
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
Stephen C. Bain et al.
DIABETES OBESITY & METABOLISM (2019)
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
Charlotte Granhall et al.
CLINICAL PHARMACOKINETICS (2018)
A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide
Tine A. Baekdal et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2018)
Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
Tine A. Baekdal et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
The kidney and cardiovascular outcome trials
Zachary Bloomgarden
JOURNAL OF DIABETES (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist
Stephen T. Buckley et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes A Randomized Clinical Trial
Melanie Davies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
M. Nauck
DIABETES OBESITY & METABOLISM (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society
Elizabeth R. Seaquist et al.
DIABETES CARE (2013)
Approaches for enhancing oral bioavailability of peptides and proteins
Jwala Renukuntla et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2013)
Glucagon-like peptide 1 and appetite
Megan J. Dailey et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2013)
Comparing the Efficacy and Tolerability of a New Daily Oral Vitamin B12 Formulation and Intermittent Intramuscular Vitamin B12 in Normalizing Low Cobalamin Levels: A Randomized, Open-Label, Parallel-Group Study
M. Cristina Castelli et al.
CLINICAL THERAPEUTICS (2011)
Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular Disease
Roland E. Schmieder et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Pharmacokinefics and pharmalcodynamics of oral heparin solid dosage form in healthy human subjects
Shaker A. Mousa et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals
HC Gerstein et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
